Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?

The approval of immune-checkpoint inhibitors (CPI) and mitogen activated protein kinase inhibitors (MAPKi) in recent years significantly improved the treatment management and survival of patients with advanced malignant melanoma. CPI aim to counter-act receptor-mediated inhibitory effects of tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Haist, Maximilian, Stege, Henner, Kuske, Michael, Bauer, Julia, Klumpp, Annika, Grabbe, Stephan, Bros, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348973/
https://www.ncbi.nlm.nih.gov/pubmed/37022618
http://dx.doi.org/10.1007/s10555-023-10097-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348973/
https://www.ncbi.nlm.nih.gov/pubmed/37022618
http://dx.doi.org/10.1007/s10555-023-10097-z

Ejemplares similares